Tourmaline Bio Inc TRML
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 25.69M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 77
- Website
- https://www.tourmalinebio.com
Valuation
|
Metric
|
TRML
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TRML
|
|---|---|
Quick Ratio | 23.70 |
Current Ratio | 24.68 |
Interest Coverage | — |
Quick Ratio
TRML
Profitability
|
Metric
|
TRML
|
|---|---|
Return on Assets (Normalized) | −26.09% |
Return on Equity (Normalized) | −26.80% |
Return on Invested Capital (Normalized) | −26.78% |
Return on Assets
TRML
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$&N$F>$ | LOCK|FydwQ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|CN&f&b | LOCK|Xr<V | $84B | |||
| Moderna Inc
MRNA
| LOCK|m#fp#%q | LOCK|DN | $83B | |||
| argenx SE ADR
ARGX
| LOCK|k?Wgx@$ | LOCK|#nZ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X^%lb&Q | LOCK|dY | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kWYrf$V | LOCK|R&m@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^$?z^qV^ | LOCK|$%D<q | $29B | |||
| Incyte Corp
INCY
| LOCK|%^##N@# | LOCK|z!< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|TgMkJ&F | LOCK|Zz | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|q@!?Z#w | LOCK|Tn | $14B |
United States